SpaceX analyst target prices flooded the market Tuesday after the mandated quiet period expired following the company's blockbuster IPO. The estimates vary wildly, rendering simple averages meaningless for investors trying to gauge fair value. Research departments at major underwriting firms almost universally initiate coverage with buy ratings, a structural conflict that rarely produces objective analysis.

History offers a cautionary tale: Snap received a rare non-buy initiation at its debut, and its shares have since plunged 80%. The current dispersion in SpaceX price targets mirrors that precedent, signaling deep disagreement about the satellite-internet venture's trajectory. When underwriters' own analysts cannot converge on a valuation range, the market lacks a reliable anchor.

For institutional allocators, the episode underscores the limits of sell-side research on freshly listed, capital-intensive ventures. The wide target spread reflects genuine uncertainty about Starlink subscriber growth, launch cadence, and regulatory hurdles across dozens of jurisdictions. Investors should treat analyst consensus as a sentiment indicator, not a valuation tool.